硼替佐米联合环磷酰胺及地塞米松治疗多发性骨髓瘤的临床疗效和毒副反应  

Efficacy and Side Effects of Bortezomib Combined with Cyclophosphamide and Dexamethasone in the Treatment of Multiple Myeloma

作　　者：鲁俊 朱熙君[1] LU Jun;ZHU Xijun(Xuancheng People's Hospital, Anhui Xuancheng 242000, China)

机构地区：[1]安徽省宣城市人民医院血液内科,安徽宣城242000

出　　处：《河北医学》2020年第4期537-540,共4页Hebei Medicine

基　　金：安徽省自然科学基金项目,(编号:81071296)。

摘　　要：目的:探讨多发性骨髓瘤(MM)硼替佐米联合环磷酰胺及地塞米松方案治疗的临床疗效和毒副反应。方法:回顾性选取2016年10月至2019年10月我院多发性骨髓瘤患者70例,依据治疗方法分为硼替佐米联合环磷酰胺及地塞米松方案治疗组(环磷酰胺组,n=35)和硼替佐米联合沙利度胺及地塞米松方案治疗组(沙利度胺组,n=35)两组,统计分析两组患者的临床疗效、毒副反应发生情况。结果:环磷酰胺组患者的深度反应率82.9%(29/35)显著高于沙利度胺组51.4%(18/35)(P<0.05)。在毒副反应发生率方面,环磷酰胺组为54.3%(19/35),沙利度胺组为60.0%(21/35),两组比较差异不显著(P>0.05)。结论:多发性骨髓瘤(MM)硼替佐米联合环磷酰胺及地塞米松方案治疗的临床疗效较硼替佐米联合沙利度胺及地塞米松方案治疗显著,且不会在极大程度上增加患者毒副反应。Objective:To investigate the clinical efficacy and side effects of bortezomib combined with cyclophosphamide and dexamethasone in the treatment of multiple myeloma(MM).Methods:70 cases of patients with multiple myeloma from October 2016 to October 2019 were divided into two groups according to the treatment,Bortezomib plus cyclophosphamide and dexamethasone group(cyclophosphamide group,n=35)and bortezomib plus thalidomide and dexamethasone group(thalidomide group,n=35).The clinical efficacy and toxicity of the two groups were statistically analyzed.Results:The deep response rate of cyclophosphamide group was 82.9%(29/35)significantly higher than that of thalidomide group 51.4%(18/35)(P<0.05).The incidence of side effects was 54.3%(19/35)in the cyclophosphamide group and 60.0%(21/35)in the thalidomide group.The difference between the two groups was not significant(P>0.05).Conclusion:The therapeutic effect of bortezomib combined with cyclophosphamide and dexamethasone is better than bortezomib combined with thalidomide and dexamethasone,and it will not increase the side effects of patients.

关 键 词：硼替佐米 环磷酰胺 地塞米松 多发性骨髓瘤 

分 类 号：R73[医药卫生—肿瘤]